Biotech Pharmaceutical Co., Ltd.
Clinical trials sponsored by Biotech Pharmaceutical Co., Ltd., explained in plain language.
-
New antibody drug aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis early-phase study tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a bispecific antibody designed to target two cancer-related proteins (EGFR and cMET). The main goals are to check the drug's …
Phase: PHASE1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug JY016 targets tough cancers with EGFR marker in early trial
Disease control Not yet recruitingThis study tests a new drug called JY016 in 228 adults with advanced solid tumors that have a protein called EGFR. The trial has two parts: first, finding the safest dose, then testing how well it works against cancers like pancreatic, lung, and colon cancer. The goal is to contr…
Phase: PHASE1, PHASE2 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug EB070 takes first step: safety check in healthy volunteers
Knowledge-focused Not yet recruitingThis early-stage study tests whether the experimental drug EB070 is safe and how the body processes it. About 36 healthy adults will receive a single injection of either EB070 or a placebo. Researchers will monitor side effects and measure drug levels in the blood for about 3 mon…
Phase: PHASE1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated May 04, 2026 16:18 UTC